Sunitinib also reduces MDSC numbers which is correlated with Treg decrease in the tumor microenvironment (23, 56) and favors CD4+ and CD8+ infiltration in the tumor site while reducing PD-1 expression on CD8+ T-cells (44, 53). The gene discussed is CD8A; the disease is neoplasm.